English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/143785
Título

Subcutaneous immunoglobulins: a promising alternative for immunomodulation?

AutorSánchez-Ramón, Silvia; Corbí, Angel L. ; Fidalgo, Á. G.; Domínguez-Soto, Ángeles
Palabras claveSubcutaneous immunoglobulin
Immunomodulation
Mechanisms of action
Fecha de publicación2016
EditorBentham Science Publishers
CitaciónCurr Pharm Des 22(41):6300-6305 (2016)
ResumenCumulative recent evidence from clinical trials, observational studies and case reports has shown that subcutaneous administration of immunoglobulin (SCIg) exerts similar immunomodulatory capacity than intravenous immunoglobulin (IVIg) in autoimmune neurological diseases. Besides the beneficial clinical effects, the profile of safety and autonomy for the patient is higher for SCIg, while it is cost-saving in terms of the health resources used. However, there are still very few approved indications for SCIg and a certain resistance to choose SCIg for other autoimmune conditions even despite patients' interests. Here we present an updated review of the known immunomodulatory mechanisms of action of Ig and the current hypothesis supporting the clinical and immunological advantages of SCIg over IVIg that derive from their specific pharmacokinetic features.
Descripción16 p.-1 tab.
Versión del editorhttp://dx.doi.org/10.2174/1381612822666160831103806
URIhttp://hdl.handle.net/10261/143785
DOI10.2174/1381612822666160831103806
ISSN1381-6128
E-ISSN1873-4286
Aparece en las colecciones: (CIB) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Current Pharm. Design 2016.docPostprint467,5 kBMicrosoft WordVisualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.